Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2003

01-06-2003

Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study

Authors: Harold J. Burstein, George D. Demetri, Elisabetta Mueller, Pasha Sarraf, Bruce M. Spiegelman, Eric P. Winer

Published in: Breast Cancer Research and Treatment | Issue 3/2003

Login to get access
Metadata
Title
Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study
Authors
Harold J. Burstein
George D. Demetri
Elisabetta Mueller
Pasha Sarraf
Bruce M. Spiegelman
Eric P. Winer
Publication date
01-06-2003
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 3/2003
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1024038127156

Other articles of this Issue 3/2003

Breast Cancer Research and Treatment 3/2003 Go to the issue

OriginalPaper

Effect of Ligands of Nuclear Hormone Receptors on Sodium/Iodide Symporter Expression and Activity in Breast Cancer Cells

OriginalPaper

Long Term Inhibition by Estradiol or Progesterone of Melatonin Secretion After Administration of a Mammary Carcinogen, the Dimethyl Benz(a)anthracene, in Sprague-Dawley Female Rat; Inhibitory Effect of Melatonin on Mammary Carcinogenesis

OriginalPaper

Progesterone Receptors A and B Differentially Affect the Growth of Estrogen-Dependent Human Breast Tumor Xenografts

OriginalPaper

Ornithine Decarboxylase (ODC) as a Prognostic Factor in Operable Breast Cancer

OriginalPaper

Incidence of Anaemia in Breast Cancer Patients Receiving Adjuvant Chemotherapy

OriginalPaper

JNK/SAPK Mediates Doxorubicin-Induced Differentiation and Apoptosis in MCF-7 Breast Cancer Cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits